Generic #drugrepurposing offers a promising tool for drug development - but a system built for pharma will never realize this potential. In our new guest commentary, we argue #FDA can take actions to fix this. www.biocentury.com/article/657654

📣JUST PUBLISHED: Our white paper on regulatory opportunities to advance generic drug repurposing is now available online! This paper explores the role of the regulator and policy actions it can take to support repurposing initiatives. @dukemargolis.bsky.social healthpolicy.duke.edu/publications...

Why can't I get over this feeling that I'm cheating when I use ChatGPT to help me write something? I know most people use it, but I have this stubbornness that tells me I'm a capable writer and shouldn't be taking short cuts. How do I get past this!? 😩

Measles and tariffs, what century is this?

It turns out it’s always veep and never house of cards

A brief timeline of the Signal group chat story so far

USAID under threat: www.nytimes.com/live/2025/02...

NIH issues a policy to widen access to medical products that emerge from government-funded research www.statnews.com/pharmalot/20... via @statnews.com

"The removal is a major win for the PBMs and the health insurers that own them." And yet, leaders are confused about why Americans are embracing vigilantism... www.statnews.com/2024/12/19/r...

📣New Publication!📣 Check out our proposed solution to help unlock the full potential of generic drugs to meet patient needs. @dukemargolis.bsky.social www.healthaffairs.org/content/fore...